Press Releases
Every day, more lives are transformed all over the world – one healthy habit at a time. Read the latest about how Medifast and the OPTAVIA® movement is impacting people’s lives.
The Glycemic Research Institute in Washington, D.C. announced today that Jason Pharmaceutical's product Medifast Plus for Diabetics has been duly submitted and approved as LOW GLYCEMIC.
The coveted Seal of Approval from the Institute designates that a food does not overly stimulate blood glucose and insulin and does not stimulate fat-storing enzymes.
Persons with insulin-related disorders, such as Syndrome X, Insulin- Resistance, Diabetes and Hypoglycemia look for the GRI Seal of Approval when selecting insulin-friendly products.
Dieters and athletes try and avoid High Glycemic foods since they stimulate insulin and fat-storage. Consumers feel that the Seal of Approval makes it easy to distinguish High Glycemic foods from those that are Low Glycemic.
Athletes seek out Low Glycemic products because they do not imbalance blood sugar levels, which is important in sports events. High glycemic food, drinks, and Nutraceuticals also impair sports performance.
SOURCE: Medifast, Inc.
Contact: Jaime M. Hershner, Director of Marketing Services of Medifast,
+1-410-581-8042, ext. 236, for Medifast
Website: http://www.medifast.net/